Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | IL17A | Q16552 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619094 | 1.00 | BRD4 (0.59) | BRD4IL17AHDAC6HDAC3NCOR1 | |
| SCHEMBL16516221 | 0.99 | BRD4 (0.60) | BRD4IL17AHDAC6HDAC3NCOR1 | |
| SCHEMBL619114 | 0.97 | BRD4 (0.58) | BRD4IL17AHDAC6HDAC3NCOR1 | |
| SCHEMBL616988 | 0.90 | BRD4 (0.51) | BRD4IL17AHDAC6HDAC3NCOR1 | |
| SCHEMBL616068 | 0.88 | BRD4 (0.46) | BRD4IL17APOLB | |
| SCHEMBL618613 | 0.87 | BRD4 (0.49) | BRD4IL17A | |
| SCHEMBL616299 | 0.85 | POLB (0.54) | BRD4IL17APOLB | |
| SCHEMBL617999 | 0.85 | BRD4 (0.44) | BRD4IL17AHDAC6 | |
| SCHEMBL347520 | 0.83 | BRD4 (0.47) | BRD4HDAC6HDAC3NCOR1HDAC1 | |
| SCHEMBL29430467 | 0.83 | BRD4 (0.47) | BRD4HDAC6HDAC3NCOR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885IL17A 226/4885HDAC6 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.